Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.22.2.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 30,691 $ 125,806
Marketable securities 122,724 60,729
Prepaid research and development expenses 668 2,371
Other prepaid expenses and current assets 1,041 2,193
Total current assets 155,124 191,099
Property and equipment, net 845 1,178
Non-current marketable securities 0 8,067
Operating lease right-of-use asset 197 254
Other assets 3,081 1,720
Total assets 159,247 202,318
Current liabilities:    
Accounts payable 479 2,728
Accrued research and development expenses 6,622 9,752
Other accrued liabilities 5,610 5,886
Total current liabilities 12,711 18,366
Development financing liability 86,152 50,320
Long-term portion of operating lease liability 206 695
Total liabilities 99,069 69,381
Commitments and contingencies
Stockholders' equity:    
Preferred stock, $0.0001 par value: 10,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.0001 par value: 200,000,000 shares authorized; 84,681,063 and 84,677,939 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively 8 8
Additional paid-in capital 906,968 899,798
Accumulated other comprehensive (loss) income (574) (13)
Accumulated deficit (846,224) (766,856)
Total stockholders' equity 60,178 132,937
Total liabilities and stockholders' equity $ 159,247 $ 202,318